Results 141 to 150 of about 40,056 (270)

The α7 nAChR Agonist PNU-282987 Reduces Inflammation and MPTP-Induced Nigral Dopaminergic Cell Loss in Mice

Journal of Parkinson’s Disease, 2013
Background: Parkinson's disease (PD) is associated with neurodegeneration of dopaminergic neurons and an accompanying neuroinflammatory process in the substantia nigra (SN).
Vanessa Stuckenholz, Michael Bacher, Monika Balzer-Geldsetzer, Daniel Alvarez-Fischer, Wolfgang H. Oertel, Richard C. Dodel, Carmen Noelker   +6 more
doaj   +1 more source

Combined Inhibition of TRPM4/NMDA Receptor Complex and Extrasynaptic NMDA Receptors Is Candidate Therapeutic Target for Suppression of Epileptic Seizures and Improvement of Cognitive Impairments

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Cognitive impairments are important therapeutic targets in epilepsy medication; however, effective pharmacological treatments for epilepsy patients with comorbid cognitive impairment have not been established. Effects of chronic administration of MK‐801 (noncompetitive NMDA receptor inhibitor), memantine (low‐affinity extrasynaptic‐NMDA ...
Motohiro Okada, Ruri Okubo, Tomoka Oka, Eishi Motomura   +3 more
wiley   +1 more source

Natural Products as the Modulators of Gut Microbiota: A Pool for the Development of New Treatment Against Obesity?

Food Frontiers, Volume 7, Issue 3, May 2026.
Natural compounds regulate gut microbiota by improving microbial balance and increasing probiotics, which boost short‐chain fatty acid production to alleviate insulin resistance and inflammation. Additionally, they stimulate appetite‐suppressing hormones through bile acid signaling, while inhibiting pathogenic bacteria to repair intestinal barrier ...
Hongchao Yuan, Yau‐Yuen Chan, Guang Chen, Lin Xu, Cheng Zhang, Guoyi Tang, Yibin Feng, Ning Wang   +7 more
wiley   +1 more source

Varenicline in the treatment of tobacco dependence

Neuropsychiatric Disease and Treatment, 2008
Karl Fagerström1, John Hughes21Smokers Information Centre, Fagerström Consulting AB, Berga Alle 1, 25452 Helsingborg, Sweden; 2University of Vermont, Burlington, Vermont, USAAbstract: Varenicline, a partial agonist of α4& ...
Karl Fagerström, John Hughes
doaj  

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Acta Psychiatrica Scandinavica, Volume 153, Issue 5, Page 402-431, May 2026.
ABSTRACT Background Schizophrenia is characterized by positive, negative, and cognitive symptoms. Current pharmacological treatments often fail to address cognitive deficits. In this review of clinical trials, we aim to identify studies that explore neurobiological (non‐psychological) strategies to address Cognitive Impairment Associated with ...
Bahareh Peyrovian, Lena Palaniyappan, Theodore T. Kolivakis, Howard C. Margolese   +3 more
wiley   +1 more source

Neurodevelopmental burden in young adults undergoing opioid substitution therapy: The role of inattentive and hyperactive/impulsive symptoms

The American Journal on Addictions, Volume 35, Issue 3, Page 412-421, May 2026.
Abstract Background and Objectives Attention‐deficit/hyperactivity disorder (ADHD) is recognized as a condition that can persist into adulthood, often with psychiatric comorbidities that worsen the overall prognosis. ADHD has been associated with substance use disorders (SUDs), especially through symptoms like hyperactivity and impulsivity, while the ...
Maddalena Cesco, Marco Garzitto, Livia Pischiutta, Tiziana Lombardelli, Enrico Moratti, Giuliano Zamparutti, Matteo Balestrieri, Umberto Albert, Marco Colizzi   +8 more
wiley   +1 more source

Anti‐inflammatory effects of physical stimuli: The central role of networks in shaping the future of pharmacological research

British Journal of Pharmacology, Volume 183, Issue 10, Page 2177-2196, May 2026.
Addressing complexity in the study of life sciences through Systems Biology and Systems Medicine has been transformative, making Systems Pharmacology the next logical step. In this review, we focus on physical stimuli, whose potential in pharmacology has been neglected, despite demonstrated therapeutic properties.
Veronica Paparozzi, Reyhaneh Hooshmandabbasi, Alessandro Ravoni, Ying Ma, Luigi Manni, Timothy J. Koh, Caroline Maake, Tiziana Guarnieri, Darong Lai, Vitalii Zablotskii, Christine Nardini   +10 more
wiley   +1 more source

Chronic Nicotine Selectively Enhances α4β2* Nicotinic Acetylcholine Receptors in the Nigrostriatal Dopamine Pathway [PDF]

, 2009
These electrophysiological experiments, in slices and intact animals, study the effects of in vivo chronic exposure to nicotine on functional α4β2* nAChRs in the nigrostriatal dopaminergic (DA) pathway.
Cai, Haijiang, Lester, Henry A., McIntosh, J. Michael, McKinney, Sheri, Nashmi, Raad, Xiao, Cheng   +5 more
core  

Profiling of HCAR1 signalling reveals Gαi/o and Gαs activation without β‐arrestin recruitment and the discovery of an allosteric agonist

British Journal of Pharmacology, Volume 183, Issue 10, Page 2219-2235, May 2026.
Abstract Background and Purpose Lactate, historically viewed as a metabolic by‐product, has emerged as a signalling molecule via the G protein–coupled receptor Hydroxycarboxylic Acid Receptor 1 (HCAR1). The receptor is primarily expressed in adipocytes but also found in various other tissues.
Simon Lind, Shane C. Wright, Emilia Gvozdenovic, Kristina Nilsson, Kenneth L. Granberg, Michel Bouvier, Linda C. Johansson   +6 more
wiley   +1 more source

Nicotinic Agonist [PDF]

, 2020
openaire   +1 more source